Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Esther Heijnen"'
Autor:
Richard H. Osborne, Lauren M. Nelson, Sheri Fehnel, Nicole Williams, Randall H. Bender, Ryan Ziemiecki, Efi Gymnopoulou, Els De Paepe, Yannick Vandendijck, Lindsey Norcross, Esther Heijnen, Gabriela Ispas, Christy Comeaux, Benoit Callendret, Eric K. H. Chan, Jane A. Scott
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Background The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the construc
Externí odkaz:
https://doaj.org/article/5b724d2c15ed41cd898aa8d9498f4137
Autor:
Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)–related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity
Externí odkaz:
https://doaj.org/article/b2aea500df0240bfbc7e6fbb96c2f5d1
Autor:
Tessa Hosman, Roy van Heesbeen, Arangassery Rosemary Bastian, Weihong Hu, Christy Comeaux, Nynke Ligtenberg, Bart van Montfort, Benoît Callendret, Esther Heijnen
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThis study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediat
Externí odkaz:
https://doaj.org/article/787203de28af43f88fb52684c0198561
Autor:
Jonathan S. Nguyen-Van-Tam, Maureen O'Leary, Emily T. Martin, Esther Heijnen, Benoit Callendret, Roman Fleischhackl, Christy Comeaux, Thao Mai Phuong Tran, Karin Weber
Publikováno v:
European Respiratory Review, Vol 31, Iss 166 (2022)
Background Respiratory syncytial virus (RSV) significantly impacts the health of older and high-risk adults (those with comorbidities). We aimed to synthesise the evidence on RSV disease burden and RSV-related healthcare utilisation in both populatio
Externí odkaz:
https://doaj.org/article/bbc75562a3ef4298b0dc057ed28b989b
Autor:
Aurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S. Patel, Flavia V. Castelli, Marcia G. Garcia, Wim T. Jansen, Ashwani Kumar Arora, Esther Heijnen
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 2, Pp 386-395 (2018)
The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent
Externí odkaz:
https://doaj.org/article/2e094cf069254e0f84dd3877a928fc85
Publikováno v:
International Journal of Infectious Diseases, Vol 85, Iss , Pp S10-S17 (2019)
Objective: To assess the long-term safety of MF59-adjuvanted trivalent influenza vaccine (aIIV3; Fluad™) in adults ≥65 years of age. Methods: Data from 36 primary vaccination and 7 re-vaccination Phase I through III trials were analyzed; 7532 sub
Externí odkaz:
https://doaj.org/article/0bb66961649e408c853460ae38bf1dd0
Publikováno v:
International Journal of Infectious Diseases, Vol 85, Iss , Pp S18-S25 (2019)
Objective: To assess the safety and immunogenicity of the MF59-adjuvanted seasonal trivalent inactivated influenza vaccine (aIIV3; Fluad) in children aged 6 months through 5 years who are at risk of influenza complications. Methods: A retrospective a
Externí odkaz:
https://doaj.org/article/d82b6d97ae28433a95a68be5b52ea2f2
Publikováno v:
International Journal of Infectious Diseases, Vol 85, Iss , Pp S26-S38 (2019)
Objective: To demonstrate the potential of an MF59-adjuvanted inactivated trivalent seasonal influenza vaccine (aIIV3; Fluad™) to improve the immune response in young children, we review the immunogenicity, efficacy, and safety/tolerability of aIIV
Externí odkaz:
https://doaj.org/article/92fa991c8aad499fb10b394cf9bfeb3b
Publikováno v:
International Journal of Infectious Diseases, Vol 85, Iss , Pp S1-S9 (2019)
Objective: Compare the immunogenicity of MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3; Fluad™) versus conventional trivalent inactivated influenza vaccine (IIV3) in an integrated dataset using a meta-analysis. Methods: In a meta-a
Externí odkaz:
https://doaj.org/article/eaf77e6350a843e087c510087455d195
Autor:
Ann R. Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery R. Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K.H. Chan, Jerald Sadoff, Macaya Douoguih, Benoit Callendret, Christy A. Comeaux, Esther Heijnen
Publikováno v:
New England Journal of Medicine. 388:609-620